Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
|Videos|February 25, 2019
What is on the Horizon for HIV Prevention?
Author(s)Contagion® Editorial Staff
Ian Frank, MD, discusses the future of HIV prevention and long-acting injectables.
Advertisement
Segment Description: Ian Frank, MD, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the future of HIV prevention and long-acting injectables.
Interview transcript (modified slightly for readability):
Contagion®: Are there any news therapies on the horizon for PrEP?
Ian Frank, MD: “The most exciting medication on the horizon for PrEP is cabotegravir which is a long-acting injectable medication.
There's a large study going on right now, being sponsored by the HIV Prevention Trial Network, that compares injectable cabotegravir versus oral tenofovir disoproxil fumarate and emtricitabine, the currently US Food and Drug Administration (FDA)-approved PrEP regimen. Cabotegravir is being evaluated as an every 2-month injection. If it's effective in that way it would alleviate the need to adhere to a daily regimen and could really transform the ease of PrEP administration and engagement so there's a lot of interest in that particular study.”
Advertisement
Related to this article
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.
Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Advertisement
Advertisement